Discipline of Pharmacy and Experimental Pharmacology, School of Biomedical Sciences and Pharmacy, University of Newcastle, University Drive, Callaghan, NSW, 2308, Australia.
Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Osteoporos Int. 2017 Jul;28(7):2035-2044. doi: 10.1007/s00198-017-3985-4. Epub 2017 Mar 17.
This review analyzes the economic costs of HF in Asia. The availability and quality of studies on the burden of osteoporosis in Asia are very scarce. There is a need to encourage more quality cost of osteoporosis studies based on standardized methods to convince healthcare authorities in implementing appropriate strategies.
Osteoporosis fractures, especially hip fractures, impose large economic costs to governments and societies. This review aimed to systematically analyze available evidence on healthcare costs associated with osteoporosis-related hip fractures (HF) in Asia.
Articles were systematically sought from databases including PubMed, EMBASE, and EBSCOHost between 2000 and 2015. Total costs associated with HF care, the cost components, and length of stays were retrieved and analyzed. Study designs were also qualitatively analyzed.
The availability of published studies on economic burden of HF in Asia is severely lacking with only 15 articles met the inclusion criteria. Even among the included studies, only two studies reported comprehensive costs evaluating all costs including indirect or intangible costs. Most studies satisfactorily reported criteria for conducting economic evaluation, but large variations existed in the methodological design. Due to study design and other influencing factors, large variation in the cost of HF treatment from US$774 to US$14,198.90 (median S$2943), representing an average of 18.95% (range: 3.58-57.05%) of the countries' 2014 GDP/capita, was observed. This highlighted the heavy burden of managing HF in Asia with about 40% of the included studies reported using more than one third of GDP/capita.
There is a paucity of burden of illness studies of osteoporosis in the Asian region. For the few available studies, there was a lack of standardization in methodological approach in evaluating the economic burden of the disease. There is a need to encourage more quality burden of illness studies of osteoporosis to inform policymakers in healthcare planning.
本综述分析了亚洲地区心衰的经济成本。亚洲地区骨质疏松症负担相关研究的可用性和质量非常有限。需要鼓励更多基于标准化方法的骨质疏松症成本研究，以说服医疗保健当局实施适当的策略。
骨质疏松症骨折，尤其是髋部骨折，给政府和社会带来了巨大的经济成本。本综述旨在系统分析亚洲地区与骨质疏松性髋部骨折（HF）相关的可用医疗保健成本的证据。
从包括 PubMed、EMBASE 和 EBSCOHost 在内的数据库中系统地检索了 2000 年至 2015 年的文章。检索并分析了与 HF 护理相关的总费用、费用构成和住院时间。还对研究设计进行了定性分析。
亚洲地区心衰经济负担的已发表研究非常有限，仅有 15 篇文章符合纳入标准。即使在纳入的研究中，也只有两项研究报告了全面的成本，评估了包括间接或无形成本在内的所有成本。大多数研究都满意地报告了进行经济评估的标准，但在方法设计上存在很大差异。由于研究设计和其他影响因素，HF 治疗费用从 774 美元到 14198.90 美元（中位数为 2943 新加坡元）不等，平均占各国 2014 年 GDP/人均的 18.95%（范围：3.58-57.05%）。这突出了亚洲地区管理 HF 的负担很重，约 40%的纳入研究报告使用了超过三分之一的 GDP/人均。
亚洲地区骨质疏松症疾病负担研究很少。对于为数不多的可用研究，在评估疾病经济负担的方法学方法上缺乏标准化。需要鼓励更多高质量的骨质疏松症疾病负担研究，为医疗保健规划中的政策制定者提供信息。
